A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension

Nura A. Mohamed, Blerina Ahmetaj-Shala, Lucie Duluc, Louise Mackenzie, Nicholas S. Kirkby, Daniel M. Reed, Paul D. Lickiss, Robert P. Davies, Gemma Freeman, Beata Wojciak-Stothard

Research output: Contribution to journalArticle

Abstract

Pulmonary arterial hypertension (PAH) is a chronicand progressive disease which continues to carry an unacceptablyhigh mortality and morbidity. The nitric oxide (NO) pathwayhas been implicated in the pathophysiology and progressionof the disease. Its extremely short half-life and systemiceffects have hampered the clinical use of NO in PAH. In anattempt to circumvent these major limitations, we have developeda new NO-nanomedicine formulation. The formulationwas based on hydrogel-like polymeric composite NO-releasingnanoparticles (NO-RP). The kinetics of NO release fromthe NO-RP showed a peak at about 120 min followed by asustained release for over 8 h. The NO-RP did not affect theviability or inflammation responses of endothelial cells. TheNO-RP produced concentration-dependent relaxations of pulmonaryarteries in mice with PAH induced by hypoxia. Inconclusion, NO-RP drugs could considerably enhance thetherapeutic potential of NO therapy for PAH.
Original languageEnglish
Pages (from-to)162-164
Number of pages3
JournalJournal of Cardiovascular Translational Research
Volume9
Issue number2
DOIs
Publication statusPublished - 9 Mar 2016

Fingerprint

Pulmonary Hypertension
Nitric Oxide
Nanomedicine
Hydrogel
Half-Life
Endothelial Cells
Inflammation
Morbidity
Mortality
Pharmaceutical Preparations

Bibliographical note

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Cite this

Mohamed, Nura A. ; Ahmetaj-Shala, Blerina ; Duluc, Lucie ; Mackenzie, Louise ; Kirkby, Nicholas S. ; Reed, Daniel M. ; Lickiss, Paul D. ; Davies, Robert P. ; Freeman, Gemma ; Wojciak-Stothard, Beata. / A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension. In: Journal of Cardiovascular Translational Research. 2016 ; Vol. 9, No. 2. pp. 162-164.
@article{01d07d0ac15f4b83afa471d353a93b41,
title = "A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension",
abstract = "Pulmonary arterial hypertension (PAH) is a chronicand progressive disease which continues to carry an unacceptablyhigh mortality and morbidity. The nitric oxide (NO) pathwayhas been implicated in the pathophysiology and progressionof the disease. Its extremely short half-life and systemiceffects have hampered the clinical use of NO in PAH. In anattempt to circumvent these major limitations, we have developeda new NO-nanomedicine formulation. The formulationwas based on hydrogel-like polymeric composite NO-releasingnanoparticles (NO-RP). The kinetics of NO release fromthe NO-RP showed a peak at about 120 min followed by asustained release for over 8 h. The NO-RP did not affect theviability or inflammation responses of endothelial cells. TheNO-RP produced concentration-dependent relaxations of pulmonaryarteries in mice with PAH induced by hypoxia. Inconclusion, NO-RP drugs could considerably enhance thetherapeutic potential of NO therapy for PAH.",
author = "Mohamed, {Nura A.} and Blerina Ahmetaj-Shala and Lucie Duluc and Louise Mackenzie and Kirkby, {Nicholas S.} and Reed, {Daniel M.} and Lickiss, {Paul D.} and Davies, {Robert P.} and Gemma Freeman and Beata Wojciak-Stothard",
note = "This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",
year = "2016",
month = "3",
day = "9",
doi = "10.1007/s12265-016-9684-2",
language = "English",
volume = "9",
pages = "162--164",
journal = "Journal of Cardiovascular Translational Research",
issn = "1937-5387",
number = "2",

}

Mohamed, NA, Ahmetaj-Shala, B, Duluc, L, Mackenzie, L, Kirkby, NS, Reed, DM, Lickiss, PD, Davies, RP, Freeman, G & Wojciak-Stothard, B 2016, 'A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension', Journal of Cardiovascular Translational Research, vol. 9, no. 2, pp. 162-164. https://doi.org/10.1007/s12265-016-9684-2

A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension. / Mohamed, Nura A.; Ahmetaj-Shala, Blerina; Duluc, Lucie; Mackenzie, Louise; Kirkby, Nicholas S.; Reed, Daniel M.; Lickiss, Paul D.; Davies, Robert P.; Freeman, Gemma; Wojciak-Stothard, Beata.

In: Journal of Cardiovascular Translational Research, Vol. 9, No. 2, 09.03.2016, p. 162-164.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension

AU - Mohamed, Nura A.

AU - Ahmetaj-Shala, Blerina

AU - Duluc, Lucie

AU - Mackenzie, Louise

AU - Kirkby, Nicholas S.

AU - Reed, Daniel M.

AU - Lickiss, Paul D.

AU - Davies, Robert P.

AU - Freeman, Gemma

AU - Wojciak-Stothard, Beata

N1 - This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PY - 2016/3/9

Y1 - 2016/3/9

N2 - Pulmonary arterial hypertension (PAH) is a chronicand progressive disease which continues to carry an unacceptablyhigh mortality and morbidity. The nitric oxide (NO) pathwayhas been implicated in the pathophysiology and progressionof the disease. Its extremely short half-life and systemiceffects have hampered the clinical use of NO in PAH. In anattempt to circumvent these major limitations, we have developeda new NO-nanomedicine formulation. The formulationwas based on hydrogel-like polymeric composite NO-releasingnanoparticles (NO-RP). The kinetics of NO release fromthe NO-RP showed a peak at about 120 min followed by asustained release for over 8 h. The NO-RP did not affect theviability or inflammation responses of endothelial cells. TheNO-RP produced concentration-dependent relaxations of pulmonaryarteries in mice with PAH induced by hypoxia. Inconclusion, NO-RP drugs could considerably enhance thetherapeutic potential of NO therapy for PAH.

AB - Pulmonary arterial hypertension (PAH) is a chronicand progressive disease which continues to carry an unacceptablyhigh mortality and morbidity. The nitric oxide (NO) pathwayhas been implicated in the pathophysiology and progressionof the disease. Its extremely short half-life and systemiceffects have hampered the clinical use of NO in PAH. In anattempt to circumvent these major limitations, we have developeda new NO-nanomedicine formulation. The formulationwas based on hydrogel-like polymeric composite NO-releasingnanoparticles (NO-RP). The kinetics of NO release fromthe NO-RP showed a peak at about 120 min followed by asustained release for over 8 h. The NO-RP did not affect theviability or inflammation responses of endothelial cells. TheNO-RP produced concentration-dependent relaxations of pulmonaryarteries in mice with PAH induced by hypoxia. Inconclusion, NO-RP drugs could considerably enhance thetherapeutic potential of NO therapy for PAH.

U2 - 10.1007/s12265-016-9684-2

DO - 10.1007/s12265-016-9684-2

M3 - Article

VL - 9

SP - 162

EP - 164

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

IS - 2

ER -